iShares Nasdaq Biotechnology Index Fund ETF News

It's a great time to be looking for opportunities in biotech as the sector is near the bottom, says MPM Capital's Dr Christiana Bardon. Biotech has been in correction over the past eight months What m

Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that

Currently, 66 ETFs are affected, but it will be added to even more funds soon.

Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss whether or not the prospect for more boosters mean anything for revenue trajectory in pharmaceutical stocks, if Chen thi

In financial markets, it's often said that cash is king. That's something to remember when it comes to the biotechnology universe due to the cost-intensive nature of developing new drugs and therapies

Biotechnology sector-related exchange traded funds are on a four-day streak and gaining momentum, breaking above their short-term trend lines. On Friday, SPDR S&P Biotech ETF (NYSEArca: XBI) rose 2.9%

Michael Yee, Jefferies equity research analyst, joins 'Closing Bell' to discuss Moderna stocks.

Brian Reynolds, chief market strategist at Reynolds Strategy, joins 'The Exchange' to discuss his outlook on the markets.

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Smart Beta ETF report for IBB

Sector ETF report for IBB

While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare se

By StoryTrading BioCrysts (NASDAQ: BCRX ) stock price hit 15-year highs since our article was published on Benzinga earlier this month, but with the oral prophylactic treatment providers 2021 financial results due out this Wednesday , some traders may be wondering whether its time to take some money off the table. A flurry of positive news and steadily rising sentiment could already be baked into the value of BCRX since StoryTrading contributor Zak Keller provided an update to our community. Technically, BCRX is up 59.5 percent in the last three months, countering iShares Biotechnology ETF (IBB), which fell 18.6 percent during the same time period. BCRX is also up more than 370 percent since the stock was presented to StoryTrading as a VIP Pick in Full story available on Benzinga.com

ETFs are a great way to approach broad plays that focus on sector allocation rather than intra-sector allocation where quality of decisions results in more marginal benefits. We think that the theme f